US appeals court confirms patent validity of Acadia's Parkinson's drug
(Reuters) -Acadia Pharmaceuticals said on Monday that the U.S. Court of Appeals has confirmed the validity of its patent for Nuplazid, its drug for hallucinations and delusions associated with Parkinson's disease.
The decision supports a December 2023 ruling from the U.S. District Court of Delaware, ensuring the patent remains protected in Acadia's legal battle against India-based drugmaker MSN Laboratories.
The appeals court followed a precedent that says an earlier patent claim cannot be invalidated by a later one if they share the same priority date.
"We are gratified that the U.S. Federal Appeals Court has affirmed the lower court's ruling in favor of our composition of matter patent for Nuplazid, securing protection into 2030 for this patent, and beyond based on the recent favorable ruling for our formulation patent providing patent protection for Nuplazid 34 mg capsule formulation into 2038," said CEO Catherine Owen Adams.
This decision comes after another favorable ruling for Acadia regarding its formulation patent for Nuplazid. The court supported Acadia's claims of infringement and validity in its legal case against Aurobindo Pharma and other companies.
The U.S. FDA approved Nuplazid for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis in 2016.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Oil inches up, outcome of US-China trade talks awaited
By Anjana Anil (Reuters) -Oil prices edged up on Tuesday as market participants waited for the outcome of U.S.-China talks that could pave the way for easing trade tensions and improve fuel demand. Brent crude futures edged up 12 cents to $67.16 a barrel at 0041 GMT. U.S. West Texas Intermediate crude was trading up 13 cents at $65.42, after hitting its highest since April 4 earlier in the session. On Monday, Brent had risen to $67.19, the highest since April 28, buoyed by the prospect of a U.S.-China trade deal. U.S.-China trade talks were set to continue for a second day in London as top officials aimed to ease tensions that have expanded from tariffs to rare earth curbs, risking global supply chain disruptions and slower growth. U.S. President Donald Trump said on Monday that the talks were going well and he was "only getting good reports" from his team in London. A trade deal between the U.S. and China could support the global economic outlook and boost demand for commodities including oil. Elsewhere, Iran said it would soon hand a counter-proposal for a nuclear deal to the U.S. in response to a U.S. offer that Tehran deems "unacceptable", while Trump made clear that the two sides remained at odds over whether the country would be allowed to continue enriching uranium on Iranian soil. Iran is the third-largest producer among members of the Organization of the Petroleum Exporting Countries and any easing of U.S. sanctions on Iran would allow it to export more oil, weighing on global crude prices. Meanwhile, a Reuters survey found that OPEC oil output rose in May, although the increase was limited as Iraq pumped below target to compensate for earlier overproduction and Saudi Arabia and the United Arab Emirates made smaller hikes than allowed. OPEC+, which pumps about half of the world's oil and includes OPEC members and allies such as Russia, is accelerating its plan to unwind its most recent layer of output cuts. "The prospect of further hikes in OPEC supply continues to hang over the market," Daniel Hynes, senior commodity strategist at ANZ, said in a note. "A permanent shift to a market driven strategy (in OPEC) would push the oil market into a sizeable surplus in H2 2025 and almost surely lead to lower oil prices." Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Rochester-based organization providing aid to Haiti reacts to international travel ban
ROCHESTER, N.Y. (WROC) – The Trump administration has imposed a travel ban on 12 countries, which took effect Monday. The ban is prohibiting those primarily in Africa and the Middle East from entering the U.S. out of concerns of national security and terrorism. Haiti is among the countries affected. News 8 spoke to the leader of one local organization overseeing mission work there for years. Dr. Ralph Pennino co-founded Intervol in the late 80s and for more than three decades, the Rochester-based organization has helped to provide countless medical supplies and equipment in developing countries each year. In 2017, Dr. Pennino helped to create a school in Leogane, Haiti, which is not far from the country's capital of Port-Au-Prince. 'Right now, we've got grades 1 through 9. These are kids that wouldn't have a choice in education otherwise,' said Dr. Pennino. Regarding the travel ban, Dr. Pennino says the future of volunteerism is unclear. With a population plagued by poverty and violence, he says it only makes matters more complicated. 'Haiti, interestingly enough, has the highest number of volunteers per capita for a population that comes down to try and help Haiti. To be quite honest, there's probably going to be a lot of repair work to do because people are going to be afraid. And I understand. They're not going to go want to go there,' said Dr. Pennino. Catholic Charities closing certain refugee resettlement programs While there's no immediate answer as to when the travel ban will lift, Intervol continues to meet with students online for services like medical checkups or educational lessons. 'We'd normally send doctors down that would go to some of the remote villages to do primary care and the surgeons would go to part of the hospital. That part of what we do, I don't know how long it's going to be,' said Dr. Pennino. Dr. Pennino added for the first time in the Haitian school's history, their ninth graders are about to complete their national exams. He says that has been a positive in the midst of uncertainty. More information on ways to donate or help support Intervol's cause in Haiti can be found here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
25 minutes ago
- Yahoo
Australia's Monash IVF reports second embryo incident in two months
(Reuters) -Australian fertility group Monash IVF on Tuesday reported a new incident related to an embryo transfer, within a couple of months after reporting a similar case where a doctor accidentally implanted the wrong embryo. The latest incident, which occurred on June 5 at the company's Clayton laboratory, has been reported to regulatory bodies and the company's insurer, Monash said, issuing an apology to the impacted couple. The company is also conducting an internal investigation. The firm added that it is implementing additional verification processes and patient confirmation safeguards to prevent similar incidents in the future. The clinic owner in April reported a similar incident where an Australian woman gave birth to a stranger's baby due to a Monash fertility doctor's error. Shares of Monash are down about 31% since the news. The mix-up has drawn attention to an industry that was largely self-regulated until recently and raised concerns about security protocols at IVF clinics. The facilities are regulated by a mix of Australian industry bodies and state government agencies.
